Mallinckrodt Delays Generics Spinoff
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.